



Security Code: 531637

Security ID: SWORDNSH

14th August, 2019

To,
The Listing Compliance Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir/ Madam,

Ref: Sword and Shield Pharma Limited (Security Code: 531637; Security ID: SWORDNSH)

Subject: Submission of Unaudited Financial Result of the Company for the Quarter ended on June 30, 2019 along with Limited Review Report.

In reference to captioned subject and Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:


1. Unaudited Financial Results for the quarter ended on June 30, 2019.
2. Limited Review Report

Kindly take the same on records and oblige.

Thanking You,

Yours Faithfully,

For, SWORD AND SHIELD PHARMA LIMITED


Ankitaben Lunagariya
Company Secretary & Compliance Officer
(ACS-55112)



SWORD AND SHIELD PHARMA LIMITED

CIN: L24231GJ1995PLC024809


Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad 380006

Website: www.swordnshieldpharma.com

Statement of Unaudited Financial Results for the quarter ended June 30, 2019

(Rs. In Lakh except per share data)

Particulars	Quarter Ended			Year Ended
	30/06/2019	31/03/2019	30/06/2018	31/03/2019
A Date of start of reporting period	01/04/2019	01/01/2019	01/04/2018	01/04/2018
B Date of end of reporting period	30/06/2019	31/03/2019	30/06/2018	31/03/2019
C Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
D Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
I Revenue From Operations				
Net sales or Revenue from Operations	-	0.76	-	1.93
II Other Income	-	0.44	-	0.45
III Total Income (I+II)	-	1.20	-	2.38
IV Expenses				
(a) Cost of materials consumed		-	-	-
(b) Purchases of stock-in-trade		-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
(d) Employee benefit expense	2.02	1.02	0.73	3.56
(e) Finance Costs	-	-	-	-
(f) Depreciation and amortisation expense	-	-	-	-
(g) Other Expenses	3.77	1.81	3.68	7.23
Legal & Professional Fees	-	0.45	0.48	1.90
Payment to Auditors	-	0.75	-	1.20
Stock Exchange Fees	3.00	-	2.95	2.95
(h) (Disclosed each and every item that is being included in Other Expenses and is more than 10% of the Total Expense)				
Total expenses (IV)	5.79	2.83	4.41	10.79
V Profit/(loss) before exceptional items and tax (III-IV)	(5.79)	(1.63)	(4.41)	(8.41)
VI Exceptional items				
VII Profit (loss) after exceptional items and before Tax (V-VI)	(5.79)	(1.63)	(4.41)	(8.41)
VIII Tax Expense	-	-	-	-
(a) Current Tax	-	-	-	-
(b) (Less):- MAT Credit	-	-	-	-
(c) Current Tax Expense Relating to Prior years	-	-	-	-
(d) Deferred Tax (Asset)/Liabilities	-	-	-	-
IX Profit (Loss) for the period from continuing operations (VII-VIII)	(5.79)	(1.63)	(4.41)	(8.41)
X Profit/(loss) from discontinued operations				
XI Tax expenses of discontinued operations				
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII A Profit(Loss) For Period Before Minority Interest	(5.79)	(1.63)	(4.41)	(8.41)
XIII B Share Of Profit / Loss of Associates and joint ventures accounted for using equity method				
XIII C Profit/Loss Of Minority Interest				
XIV Profit (Loss) for the period (XIII A + XIII B + XIII C)	(5.79)	(1.63)	(4.41)	(8.41)
XV Other Comprehensive Income				
a. i). Items that will not be reclassified to profit or loss	-	-	-	-
ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
b i). Item that will be reclassified to profit or loss	-	-	-	-
ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Comprehensive income	-	-	-	-
XVI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)	(5.79)	(1.63)	(4.41)	(8.41)
XVII Details of equity share capital				
Paid-up equity share capital	51,506,000.00	51,506,000.00	51,506,000.00	51,506,000.00
Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-



SWORD AND SHIELD PHARMA LIMITED

CIN: L24231GJ1995PLC024809

Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad 380006

Website: www.swordnshieldpharma.com

Statement of Unaudited Financial Results for the quarter ended June 30, 2019

(Rs. In Lakh except per share data)


Particulars	Quarter Ended			Year Ended
	30/06/2019	31/03/2019	30/06/2018	31/03/2019
A Date of start of reporting period	01/04/2019	01/01/2019	01/04/2018	01/04/2018
B Date of end of reporting period	30/06/2019	31/03/2019	30/06/2018	31/03/2019
C Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
D Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
XIX Earnings per share				
(a) Earnings per share (not annualised for quarter ended)				
Basic earnings (loss) per share from continuing operation	(0.11)	(0.03)	(0.09)	(0.16)
Diluted earnings (loss) per share from continuing operation	(0.11)	(0.03)	(0.09)	(0.16)
(b) Earnings per share (not annualised for quarter ended)				
Basic earnings (loss) per share from discontinued operation	-	-	-	-
Diluted earnings (loss) per share from discontinued operation	-	-	-	-
(c) Earnings per share (not annualised for quarter ended)				
Basic earnings (loss) per share from continuing and discontinued operations	(0.11)	(0.03)	(0.09)	(0.16)
Diluted earnings (loss) per share continuing and discontinued operations	(0.11)	(0.03)	(0.09)	(0.16)

Notes on Financial Results:-

- 1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on August 14, 2019.
- 2 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April 2017.
- 3 The format of the above results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with the requirements of SEBI's Circular dated 5th July, 2016, Ind AS and Schedule III [Division II] to the Companies Act 2013.
- 4 The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI [Listing Obligation and Disclosure Requirements] Regulations, 2015. The corresponding Ind AS compliant figures of the previous year have not been subjected to review/audit. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its results.
- 5 Previous year's/period's figure have been regrouped/rearranged wherever necessary.

For, Sword and Shield Pharma Limited

Date : 14-Aug-19
Place:- Ahmedabad




Pravinbhai Patel
Managing Director
DIN: 01877446



B. K. PATEL & CO

Chartered Accountants

401-404, VRAJ Valencia, B/h. Mahindra Show Room, Nr. Sola Overbridge,
S.G. Highway, Sola, AHMEDABAD-380 060, Gujarat.
Phone : 079-2970 0974/75 • Email: bkpatelandco@gmail.com

Limited Review Report

To,
The Board of Directors,
Sword & Shield Pharma Limited.
Ahmedabad

We have reviewed the accompanying statement of unaudited Quarterly Financial Results (the statements) together with the relevant notes thereon of **Sword & Shield Pharma Limited**, Ahmedabad for the quarter ended on **June 30, 2019** prepared by the Company in pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a review report on these financial statements based on our review of the statement, which has been prepared by the Management in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July, 2016 (hereinafter referred to as the SEBI Circular), and other accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by Independent Auditor of Entity" issued by The Institute of Chartered Accountants of India which requires that we plan and perform the review to obtain moderate assurance as to whether the financial information's are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is subsequently less in scope than an audit conducted in accordance with standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified during the course an Audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with Indian accounting standards (Ind AS 34) as specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 the SEBI Circular and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, or that it contains any material misstatement.

Ahmedabad
13-8-2019



For, B. K. PATEL & CO
Chartered Accountants
Firm Regn No. 112647W

K. D. Patel
Partner

Membership No. 39919
UDIN : 19039919AAAABZ8913